RT Journal Article
SR Electronic
T1 Triple therapy with Fluticasone furoate/Umeclidinium/Vilanterol compared with dual bronchodilation or triple therapy with inhaled corticosteroids/dual bronchodilation in patients with chronic obstructive pulmonary disease
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 3276
DO 10.1183/13993003.congress-2020.3276
VO 56
IS suppl 64
A1 Naoko Harada
A1 Kengo Otsuka
A1 Atsuo Horiuchi
A1 Yoko Shinka
A1 Hiroyuki Yamamura
A1 Naoki Miyao
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/3276.abstract
AB Background and Aims: Previous study showed triple therapy with Fluticasone furoate/Umeclidinium /Vilanterol(FF/UME/VI) reduced exacerbations versus dual therapies. However, treatment response to inhaled corticosteroids(ICS) is unstable in patients with chronic obstructive pulmonary disease(COPD). We aimed to know the efficacy of ICS to lung function in triple therapy.Methods: Patients (n=104) with COPD were medicated by two or three therapies sequentially. These therapies are with FF/UME/VI or dual bronchodilation(:Umeclidinium/Vilanterol(UME/VI), Glycopyrronium /Indacaterol(GLY/IND), Tiotropium/Olodaterol(TIO/OLO)) or triple therapy consisting in ICS/dual bronchodilation in each device. In every therapy, we measured lung function(FEV1, IC) and COPD assessment test(CAT) score for comparison.Results and Conclusions: CAT score with FF/UME/VI(14.1±8.0 vs 16.1±8.3(p=0.36)) or dual bronchodilation (11.8±6.0 vs 16.1±8.3(p=0.02)) was lower than with another triple therapy. FF/UME/VI had a tendency to improve FEV1 more than dual bronchodilation(1.73±0.60 vs 1.70±0.56(p=0.19)) or another triple thrapy(1.40±0.63 vs 1.38±0.65(p=0.25)). In contrast, IC was inclined to decrease with FF/UME/VI compared with dual bronchodilation(2.03±0.57 vs 2.04±0.56(p=0.69)) or another triple therapy (1.94±0.64 vs 2.00±0.65(p=0.08)) . ICS of triple therapy in one device may be contributable to improvement of air way obstruction, but may not effect on inspiratory capacity.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3276.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).